Sign In
Buy GPC
$97.07
-1.08 (-1.10%)
At Close: Jun 08, 2026
Ping Identity Celebrates Identity Excellence Award Winners 2024
12:00pm, Thursday, 12'th Dec 2024
DISH, Truckstop, Western Union, FedEx, United Airlines and GPC recognized for identity excellence DENVER , Dec. 12, 2024 /PRNewswire/ -- Ping Identity, a leader in securing digital identities for the
Top Value Managers Are Buying These 4 Stocks
11:10am, Tuesday, 03'rd Dec 2024
#Morningstar #TopValueStocks #stockinvesting Here's where some of the best managers are finding new opportunities in today's market. 00:00 Introduction 00:20 Lululemon LULU 00:56 Air Products and C
5 Dividend Aristocrats to Buy Now and Hold Through 2025
07:45am, Tuesday, 03'rd Dec 2024
Dividend Aristocrats are an attractive group of stocks for dividend growth investors because of their blue chip quality and proven track record. The stocks pay reliable dividends and grow their distri
My Top 10 High-Yield Dividend Stocks For December 2024
09:24pm, Sunday, 01'st Dec 2024
SPY continues its strong run in 2024 with a gain of +5.96% in November. The top 10 stocks on the watchlist for December 2024 offer a 3.34% dividend yield, more than double the S&P 500. My top 10 list
Genuine Parts Company Declares Regular Quarterly Dividend
04:30pm, Tuesday, 19'th Nov 2024
ATLANTA , Nov. 19, 2024 /PRNewswire/ -- Genuine Parts Company (NYSE: GPC), a leading global service provider of automotive and industrial replacement parts and value-added solutions, announced today
Top Dividend Aristocrats To Buy Now After The Trump Sweep
07:00am, Saturday, 09'th Nov 2024
A potential 15% corporate tax rate could trigger a significant rally, similar to the 2017 euphoria, boosting S&P 500 earnings by 4%. Focus on undervalued, high-quality dividend aristocrats in consumer
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
07:30am, Friday, 08'th Nov 2024
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeu
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
09:05am, Tuesday, 05'th Nov 2024
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA , Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM
My Top 10 High-Yield Dividend Stocks For November 2024
07:15am, Sunday, 03'rd Nov 2024
SPY's 5 month positive streak comes to an end in October as it posts a loss of 0.89%. The top 10 stocks on the watchlist for November 2024 offer a 3.61% dividend yield, more than double the S&P 500. M
Genuine Parts Stock: Not Cheap Enough To Buy, Yet
04:25pm, Tuesday, 29'th Oct 2024
Assessing risk vs. reward is crucial for stock investing; Genuine Parts Company's recent 20% drop prompts a re-evaluation of its current investment potential. Treat Genuine Parts' current downturn as
My Best Dividend Aristocrats For November 2024
11:23am, Tuesday, 29'th Oct 2024
The ProShares S&P 500 Dividend Aristocrats ETF went on a great run during Q3, gaining 11.6% during the quarter. I present 3 strategies that can theoretically beat the dividend aristocrat index in the
Interpreting Genuine Parts (GPC) International Revenue Trends
10:15am, Monday, 28'th Oct 2024
Explore how Genuine Parts' (GPC) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Why Genuine Parts Stock Investors Saw Red This Week
12:39pm, Thursday, 24'th Oct 2024
Shares fell after the company lowered 2024 earnings expectations.
Genuine Parts Company: Rating Downgrade On Weak Near-Term Outlook
11:42am, Thursday, 24'th Oct 2024
I downgrade Genuine Parts Company stock from buy to hold due to poor 3Q24 performance and a weak macroeconomic outlook impacting both APG and IPG segments. 3Q24 results showed disappointing comparable
SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in
